Submitted by admin on Mon, 09/17/2018 - 12:19
Date

Dendritic cells, leaders of immunity orchestras, are promising targets for vaccination or immunotherapy. However, their medical use is limited by the inability to produce large quantities of the best dendritic cells in vitro to activate lymphocytes capable of killing tumor or infected cells. The study published in the journal Cell Reports now makes it possible to consider using this type of dendritic cells as a cancer vaccine, particularly to improve the effect of immune control point inhibitors.
 

More
Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity.
Balan S, Arnold-Schrauf C, Abbas A, Couespel N, Savoret J, Imperatore F, Villani AC, Vu Manh TP, Bhardwaj N, Dalod M.
Cell Rep. 2018 Aug 14;24(7):1902-1915.e6. doi: 10.1016/j.celrep.2018.07.033.
 

Contact
Marc Dalod
Centre d’Immunologie de Marseille-Luminy (CIML),
CNRS UMR7280, Inserm U1104, AMU UNIV UM2,
163 avenue de Luminy,
13288 Marseille cedex 09.
Tél. +33 4 91 26 94 51
e-mail

CNRS INSB news